Profoot, Inc. v. Merck & Co., Inc.

663 F. App'x 928
CourtCourt of Appeals for the Federal Circuit
DecidedOctober 26, 2016
Docket2016-1216
StatusUnpublished

This text of 663 F. App'x 928 (Profoot, Inc. v. Merck & Co., Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Profoot, Inc. v. Merck & Co., Inc., 663 F. App'x 928 (Fed. Cir. 2016).

Opinion

Prost, Chief Judge.

ProFoot, Inc. (“ProFoot”) appeals from a stipulated judgment of noninfringement entered by the United States District Court for the Northern District of Illinois in favor of Merck & Co., Inc. (“Merck”), following claim construction of U.S. Patent No. 6,845,568 (“’568 patent”). For the reasons stated below, we affirm.

BACKGROUND

ProFoot is the owner of the ’568 patent, entitled “High Performance Foot Bed for Sports Equipment.” The invention is a method for providing custom footwear inserts for sports that involve symmetrical, side-to-side movement, such as skiing, skating, and cycling. ’568 patent col. 111. 9-12. The inserts “position[ ] the ankle joint or sub taylor [sic] joint in a relaxed position by correcting the pronationp[ 1 ] of the foot.” Id. at col. 1 11. 13-15. This reduces non-functional tension in the subtalar joint, which “increases the amount of relatedness between the foot and ankle joint” and allows the athlete to move side-to-side (e.g., shifting weight when making turns down a ski hill) with greater agility. Id. at col. 1 11. 45-50, col. 2 11. 23-28. The ’568 patent touts that its solution is superior to prior art solutions, because it determines *930 this “relaxed position” while an athlete is standing on one foot, instead of on two. Id. at col. 211. 5-7.

To determine the insert that is best for a particular athlete, the patent teaches the use of a special device called a “neutralizer.” Id. at abstract, col. 3 11. 1-15. The athlete steps on the “neutralizer” one foot at a time, and a fitting specialist uses the “neutralizer” to determine what angle the foot should be in to place the ankle in a “neutral position.” Id. at col. 5 11. 11-15. The specification explains that “[t]o achieve a neutral position, the operator visually examines the tendons by the ankle until they are in a relaxed state or are working equally.” Id. at col. 4 11. 22-24. It also discloses two different embodiments of the “neutralizer,” shown in Figures 1 and 2:

[[Image here]]

Claims 1 and 3 are asserted. They recite:

1. A method of fitting an individual with right and left foot inserts which place the ankles of the individual in a neutral position comprising the steps of:
for creating a right foot insert, having the individual place the right foot on a *931 neutralizer while elevating the left foot off of the neutralizer,
using the neutralizer to determine the angle necessary to place the right ankle in a neutral position;
providing an insert having an angle which represents the neutral state for the right ankle;
for creating a left foot insert, having the individual place the left foot on a neutralizer while elevating the right foot off of the neutralizer;
using the neutralizer to determine the angle necessary to place the left ankle in a neutral position; and
providing an insert having an angle which represents the neutral state for the left ankle.
[[Image here]]
3. The method of claim 1 wherein said insert is provided to a user by selecting said insert from a plurality of predetermined inserts.

’568 patent col. 5 1. 14-col. 6 1. 14 (emphases added).

On June 17, 2015, the district court construed the terms “neutralizer” and “neutral position,” as well as four others. The district court construed “neutralizer” as “a device that has a housing, a protractor, and an angularly adjustable plate capable of supporting the foot.” J.A. 10. It construed “neutral position” as “a position in which subtalar joint is in the relaxed position due to the lack of pronation or supination.” J.A. 12.

Based on the district court’s constructions, the parties stipulated to a judgment of noninfringement of all of the asserted claims of the ’568 patent. The district court entered final judgments under Rule 54(b) of the Federal Rules of Civil Procedure.

ProFoot now appeals. We have jurisdiction pursuant to 28 U.S.C. § 1295(a)(1).

Discussion

A claim term’s ultimate construction is a question of law reviewed de novo, while underlying factual determinations are reviewed for clear error. Teva Pharm. USA, Inc. v. Sandoz, Inc., — U.S. —, 135 S.Ct. 831, 842, — L.Ed.2d — (2015). “When the district court reviews only evidence intrinsic to the patent (the patent claims and specifications, along with the patent’s prosecution history), the judge’s determination will amount solely to a determination of law, and the Court of Appeals will review that construction de novo.” Id. at 841.

ProFoot challenges the district court’s construction of two claim terms: (1) “neutralizer,” and (2) “neutral position.” The parties agree that, under the district court’s construction of “neutralizer” alone, Merck does not infringe the ’568 patent. Oral Argument at 1:30-2:01, 23:55-24:26, available at http://oralarguments.cafc. uscourts.gov/default.aspx?fl=2016-1216.mp 3. Because we agree that the district court correctly construed this term, we do not reach “neutral position.”

With respect to “neutralizer,” ProFoot argues that the district court erred by naming specific components that comprise the neutralizer (e.g., a housing, a protractor, and an angularly adjustable plate capable of supporting the foot) in its construction. In ProFoot’s view, this construction is too narrow because the claims are silent as to what components comprise the neutralizer, and a person of ordinary skill in the art would recognize that a “neutralizer” is simply just some kind of measuring device. ProFoot posits that the district court relied too heavily on the ’568 patent’s specification and also the prosecution history from the parent to the ’568 patent, U.S. Patent No. 6,564,465 (“the parent ’465 patent”), nei *932 ther of which it contends are controlling. We address each in turn.

The words of a claim are generally given their ordinary and customary meaning, which is the meaning that the term would have to a person of ordinary skill in the art at the time of the invention. Phillips v. AWH Corp., 415 F.3d 1303, 1312-13 (Fed. Cir. 2005) (en banc). Claim terms “do not stand alone,” but “must be read in view of the specification, of which they are a part.” Id. at 1315 (citation omitted).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

ICU Medical, Inc. v. Alaris Medical Systems, Inc.
558 F.3d 1368 (Federal Circuit, 2009)
Ormco Corp. v. Align Technology, Inc.
498 F.3d 1307 (Federal Circuit, 2007)
Virnetx, Inc. v. Cisco Systems, Inc.
767 F.3d 1308 (Federal Circuit, 2014)
Trustees of Columbia Univ. v. Symantec Corporation
811 F.3d 1359 (Federal Circuit, 2016)
Gpne Corp. v. Apple Inc.
830 F.3d 1365 (Federal Circuit, 2016)
Teva Pharm. United States, Inc. v. Sandoz, Inc.
135 S. Ct. 831 (Supreme Court, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
663 F. App'x 928, Counsel Stack Legal Research, https://law.counselstack.com/opinion/profoot-inc-v-merck-co-inc-cafc-2016.